COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study

Harith Kh. Al-Qazaz 1, Luma M. Al-Obaidy 1, Heba M. Attash 1

Received (first version): 31-May-2022  Accepted: 08-Jun-2022  Published online: 10-Jun-2022

Abstract
The vaccine was the only way to fight against Coronavirus-19 (COVID-19) from its statement as a pandemic till day. COVID-19 vaccines were approved by the world health organization (WHO) in December 2020. Despite a large number of studies regarding the efficacy and safety of COVID-19 vaccines, to our knowledge, there were limited studies that outlined the gender disparity towards COVID-19 vaccine adverse effects. This study aims to outline the variety of side effects among men and women after getting COVID-19 vaccines (either single or two doses). It is a cross-sectional study accomplished electronically from September to November 2021. The participants involved were 843 Health Care Workers (HCWs) from different cities in Iraq. The majority of respondents were females (664). Around 65% of males experienced adverse effects compared to 77% of females. A high frequency of severe pain was reported among females. Regarding dermatological reactions like swelling, redness and skin rash were also higher reported among female subjects. In addition to that, higher frequencies of moderate and severe systemic adverse effects and mild to moderate nausea was also reported more frequently among females. In terms of cardiopulmonary adverse effects, all the reported adverse effects were found more frequently among females.

In conclusion, COVID-19 vaccines produced limited adverse effects and the majority of them were reported among women. This may be associated with hormonal and psychological factors related to them.

Keywords: COVID-19; Vaccination; Side effects

INTRODUCTION
COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It has been spread at an exponential rate all over the world and was declared a global pandemic in March 2020 by the WHO.1 From the announcement of COVID-19 as a pandemic today, the only option to eliminate it is to synthesize and develop an effective and safe vaccine.2 Furthermore, the preferred option is an efficiently safe vaccine that does not cause serious side effects.3 WHO approved the release of COVID-19 vaccines in December 2020.4 In March 2021, Iraqis began to receive the COVID-19 vaccines following registration. The provided vaccines in Iraq were Pfizer-BioNTech, Oxford-AstraZeneca and Sinopharm.

Health care workers are already at high risk of acquiring the infection, so the WHO considered them the first group to receive the vaccination.5 However, with the rapid rate of production of vaccines, many concerns about their safety have emerged.5 Some adverse effects were reported after the release of COVID-19 vaccines to general populations in different countries around the world.1,3 The biological differences between men and women are believed to contribute to gender-specific vaccination responses.6 During the COVID-19 pandemic, the important influence of gender and sex has been highlighted.7 Males have nearly three times the risk of being admitted to the intensive care as well as a 40% higher mortality risk from COVID-19 than females, although both of them have relatively the same incidence of infection. Some of the reported disparities are explained by the variation of the biological factors in innate and adaptive immune responses to COVID-19 vaccines.8 Women, on the other hand, had a considerably higher efficacy.8 Women, on the other hand, had a considerably higher risk of adverse effects than men.9 According to the reported data of study done by Riad et al, females were more likely than males to experience post-vaccination adverse effects.5 In a study achieved by Hoffman et al., in Germany, also the occurrence and severity of post-vaccination side effects were

Harith Kh. AL-QAZAZ. Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Ninevah 81011, Iraq. al_qazaz73@uomosul.edu.iq
Luma M. AL-OBAIDY. Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Ninevah 81011, Iraq. l.m.saadallah@uomosul.edu.iq
Heba M. ATTASH*. Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Ninevah 81011, Iraq. heba.attash@uomosul.edu.iq
higher in women. This study aimed to compare males and females in aspects regarding the incidence and severity of adverse effects after receiving COVID-19 vaccines.

METHOD

Study design and participants: This is an online retrospective cross-sectional study using an electronic form to collect information from the participants. The participants of the study were recruited using a convenience sampling approach. The study was conducted between September and November 2021 to evaluate COVID-19 vaccine adverse reactions among HCWs in Iraq. The participants involved were 843, aged between 23 and 61 years old from different cities in Iraq. The inclusion criteria were any Iraqi HCWs received one of COVID-19 vaccines (single or double doses). While the exclusion criteria included: non-vaccinated Iraqi HCWs and general population.

Measurement tools

The participants’ information was collected electronically using a self-administered survey developed by Google form which was available online. Only one response was allowed to be submitted by each participant. Answers were checked carefully to prevent the duplication of the responses. Web-sites and online techniques (social media such as Telegram, Facebook and Messenger) were used to distribute the questionnaire to a variety of medical groups.

The questionnaire

Demographic information: section one of the survey asked about the respondents’ demographic (gender, age, occupation, vaccine type and dose, previous infection of COVID-19, and the occurrence of any adverse effects after the vaccine. Section two included closed-ended questions (multiple-choice questions) describing the vaccine’s main systemic and local adverse effects. Single open question had been added to describe unpredicted adverse events and additional questions were included to describe whether any medical advice, analgesic, or corticosteroid use (n=635) was sought among the total participants. A non-vaccinated Iraqi HCWs and general population were evaluated separately among males and females using both the Chi-square test and Fisher exact test. A statistical significant of p-value is considered of less than 0.05%.

RESULTS

A total of 843 individuals were survived with the average age (SD) of the study population was 32.39 (6.88). The average years of experience was 7.96 (6.79). There were 664 (78.8%) females and 179 (21.2%) males among the total participants. The higher percentage of younger respondents were male (51.4%) compared with female (37.9%). 84.9% of male respondents have completed their second vaccine’s dosage. The Pfizer vaccine was used mostly among the study participants. The fundamental demographic features of the study participants was shown in Table 1. A significant association between age, experience years, vaccination status, vaccine type, and the appearance of adverse effects.

Table 1. The participants’ basic demographic characteristics

| Variable                      | Sex       | P-value |
|-------------------------------|-----------|---------|
|                               | Men (179) | Women (664) |   |
| Age (n%)                      |           |         | 0.003 |
| 20 – 29 years                 | 92 (51.4) | 249 (37.5) |   |
| 30 – 39 years                 | 65 (36.3) | 318 (47.9) |   |
| 40 years and older            | 22 (12.3) | 97 (14.6)   |   |
| Specialty                     |           | 0.599   |         |
| Doctors                       | 94 (52.5) | 321 (48.3) |   |
| Dentists                      | 39 (21.8) | 153 (23.0) |   |
| Pharmacists                   | 46 (25.7) | 190 (28.6) |   |
| Graduation level              |           | 0.322   |         |
| Graduated                     | 146 (81.6)| 519 (78.2) |   |
| Postgraduates                 | 33 (18.4) | 145 (21.8) |   |
| Years of Experience           |           | 0.004   |         |
| < 5 years                     | 86 (48.0)| 229 (34.5) |   |
| 5 – 9 years                   | 45 (25.1)| 184 (27.7) |   |
| 10 – 14 years                 | 24 (13.4)| 146 (22.0) |   |
| 15 – 19 years                 | 7 (3.9)  | 50 (7.5)   |   |
| 20 years and more             | 17 (9.5) | 55 (8.3)   |   |
| Vaccination status            |           | 0.006   |         |
| One dose only                 | 27 (15.1)| 165 (24.8) |   |
| Two doses                     | 152 (84.9)| 499 (75.2)|   |
| Type of vaccine               |           | 0.021   |         |
| Sinopharm                     | 37 (20.7)| 117 (17.6) |   |
| AstraZeneca                   | 51 (28.5)| 136 (20.5) |   |
| Pfizer                        | 91 (50.8)| 411 (61.9) |   |
| Symptoms                      |           | 0.000   |         |
| Yes                           | 116 (65) | 512 (77)  |   |
| No                            | 63 (35)  | 152 (23)  |   |
| Onset of symptoms (n=628)     |           | 0.049   |         |
| After the first vaccine dose   | 53 (45.7)| 218 (42.6) |   |
| After the second dose          | 30 (25.9)| 93 (18.2)  |   |
| After the first and second dose| 33 (28.4)| 201 (39.3)|   |
| The previous infection's history|         | 0.285   |         |
| Infected                      | 90 (50.3)| 304 (45.8) |   |
| Not infected                  | 89 (49.7)| 360 (54.2) |   |
| Corticosteroid use (n=635)    |           | 0.081   |         |
| Yes                           | 20 (14.4)| 46 (9.3)  |   |
| No                            | 119 (85.6)| 450 (90.7)|   |

The protocol of the study was approved by the University of Mosul’s Medical Research Ethics Collegiate Committee, CCMRE-phA-22-6. The participants were notified that their participation in the survey was optional so their consent should obtained before answering the questions.

Statistical analysis

The research data was collected using Google Forms. For entering data, Excel 10 (Microsoft, Albuquerque, NM, USA) was used, while for coding and analysis of data, SPSS version 25 (IBM SPSS Statistics for Windows, USA) was used. By employing means, standard deviation and other descriptive statistics, different demographic parameters (sex, age, specialty, duration of working experience, type of vaccine, doses number, symptoms incidence) were compared. The frequency of adverse effects, analgesic type and consultation of the doctor

www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X)

© the Authors
Side effects of vaccines

After receiving their vaccines, all respondents were asked whether they experienced any side effects. Only 116 (65%) males out of 843 participants said that they had experienced side effects compared to 512 (77%) females. Table 2 shows the distribution of the reported side effects in both genders. Females were shown to have a higher frequency (25.3%) of severe pain than males (14.0%) according to Table 2 and the Chi-square test. Regarding the dermatological reactions such as redness, skin rash and swelling were also highly distributed in females (p<0.05). Concerning systemic symptoms such as headache, tiredness, fever, myalgia and chills, females had significantly greater rates of severe and moderate adverse effects (p<0.05). In respect to GIT symptoms, females experienced mild to moderate nausea at a higher frequency than males (p<0.05). All the reported cardiopulmonary adverse

Table 2. The distribution of side effects among the study groups

| Variable                        | Sex          | P-value |
|---------------------------------|--------------|---------|
|                                 | Men          | Women   |
| The adverse effect of vaccination | Yes          | 116 (65) | 512 (77) | 0.000   |
|                                 | No           | 63 (35)  | 152 (23) |
| Pain at site of injection       | None         | 16 (8.9) | 27 (4.1) | 0.002   |
|                                 | Mild         | 50 (27.9)| 169 (25.5)|
|                                 | Moderate     | 88 (49.2)| 300 (45.2)|
|                                 | Sever        | 25 (14.0)| 168 (25.3)|
| Dermatological                  | Redness      | 151 (84.4)| 473 (71.2)| 0.004   |
|                                 | Mild         | 24 (13.4)| 148 (22.3)|
|                                 | Moderate     | 3 (1.7)  | 33 (5.0)  |
|                                 | Sever        | 1 (0.6)  | 10 (1.5)  |
|                                 | Swelling     | 133 (74.3)| 380 (57.2)| 0.000   |
|                                 | Mild         | 40 (22.3)| 190 (28.6)|
|                                 | Moderate     | 6 (3.4)  | 79 (11.9) |
|                                 | Sever        | 0 (0.0)  | 15 (2.3)  |
|                                 | Skin rash    | 174 (97.2)| 641 (96.5)| 0.048   |
|                                 | Mild         | 1 (0.6)  | 19 (2.9)  |
|                                 | Moderate     | 2 (1.1)  | 1 (0.2)   |
|                                 | Sever        | 2 (1.1)  | 3 (0.5)   |
| Systemic reactions              | Tiredness    | 73 (40.8)| 137 (20.6)| 0.000   |
|                                 | Mild         | 54 (30.2)| 154 (23.2)|
|                                 | Moderate     | 37 (20.7)| 220 (33.1)|
|                                 | Sever        | 15 (8.4) | 153 (23.0)|
|                                 | Headache     | 88 (49.2)| 248 (37.3)| 0.000   |
|                                 | Mild         | 52 (29.1)| 158 (23.8)|
|                                 | Moderate     | 24 (13.4)| 166 (25.0)|
|                                 | Sever        | 15 (8.4) | 92 (13.9) |
|                                 | Myalgia      | 73 (40.8)| 194 (29.2)| 0.003   |
|                                 | Mild         | 51 (28.5)| 167 (25.2)|
|                                 | Moderate     | 36 (20.1)| 184 (27.7)|
|                                 | Sever        | 19 (10.6)| 119 (17.9)|

| Variable                        | Chills        | P-value |
|---------------------------------|---------------|---------|
|                                 | None          | 124 (69.3)| 382 (57.5)| 0.008   |
|                                 | Mild          | 33 (18.4)| 126 (19.0)|
|                                 | Moderate      | 14 (7.8) | 89 (13.4) |
|                                 | Sever         | 8 (4.5)  | 67 (10.1) |
|                                 | Fever         | 90 (50.3)| 249 (37.5)| 0.011   |
|                                 | None          | 34 (19.0)| 164 (24.7)|
|                                 | Mild          | 32 (17.9)| 169 (25.5)|
|                                 | Moderate      | 23 (12.8)| 82 (12.3) |
|                                 | Transient visual disturbances | None | 162 (90.5)| 586 (88.3)| 0.348 |
|                                 | Mild          | 15 (8.4)| 60 (9.0)  |
|                                 | Moderate      | 3 (1.7)  | 16 (2.4)  |
|                                 | Sever         | 2 (1.1)  | 2 (0.3)   |
|                                 | Burning sensation of eye | None | 166 (92.7)| 588 (88.6)| 0.038 |
|                                 | Mild          | 9 (5.0)  | 48 (7.2)  |
|                                 | Moderate      | 0 (0.0)  | 21 (3.2)  |
|                                 | Sever         | 4 (2.2)  | 7 (1.1)   |

| Variable                        | Nausea (n=502)| P-value |
|---------------------------------|---------------|---------|
|                                 | None          | 147 (82.1)| 454 (68.4)| 0.000   |
|                                 | Mild          | 26 (14.5)| 114 (17.2)|
|                                 | Moderate      | 3 (1.7)  | 69 (10.4) |
|                                 | Sever         | 3 (1.7)  | 27 (4.1)  |
|                                 | Vomiting      | 175 (97.8)| 627 (94.4)| 0.053   |
|                                 | None          | 2 (1.1)  | 20 (3.0)  |
|                                 | Mild          | 2 (1.1)  | 15 (2.3)  |
|                                 | Moderate      | 0 (0.0)  | 2 (0.3)   |
|                                 | Sever         | 2 (1.1)  | 4 (0.6)   |
|                                 | Diarrhea      | 156 (87.2)| 589 (88.7)| 0.593   |
|                                 | None          | 17 (9.5) | 49 (7.4)  |
|                                 | Mild          | 4 (2.2)  | 22 (3.3)  |
|                                 | Moderate      | 2 (1.1)  | 4 (0.6)   |
|                                 | Sever         | 34 (6.8) | 15 (2.3)  |

| Variable                        | Difficulty in breathing | P-value |
|---------------------------------|-------------------------|---------|
|                                 | None                    | 164 (91.6)| 570 (85.8)| 0.052   |
|                                 | Mild                    | 9 (5.0)  | 77 (11.6) |
|                                 | Moderate                | 6 (3.4)  | 15 (2.3)  |
|                                 | Sever                   | 0 (0.0)  | 2 (0.3)   |
|                                 | Palpitation             | 153 (85.5)| 505 (76.1)| 0.025   |
|                                 | None                    | 14 (7.8) | 110 (16.6)|
|                                 | Mild                    | 10 (5.6) | 37 (5.6)  |
|                                 | Moderate                | 2 (1.1)  | 12 (1.8)  |
|                                 | Sever                   | 33 (5.0) | 35 (5.0)  |
|                                 | Sore throat             | 148 (82.7)| 497 (74.8)| 0.028   |
|                                 | None                    | 26 (14.5)| 121 (18.2)|
|                                 | Mild                    | 1 (0.6)  | 33 (5.0)  |
|                                 | Moderate                | 4 (2.2)  | 13 (2.0)  |
|                                 | Others (minors)         | Joint pain | 2 (50.0)| 5 (16.1) |
|                                 |                         | Back pain  | 0 (0.0)  | 4 (12.9) |
|                                 |                         | Somnolence  | 0 (0.0)  | 6 (19.4) |
|                                 |                         | Metallic taste | 0 (0.0) | 4 (12.9) |
|                                 |                         | Insomnia    | 2 (50.0)| 8 (25.8) |
|                                 |                         | Lymphadenopathy | 0 (0.0) | 4 (12.9) |
|                                 | Use of analgesia (n=692) | Yes | 104 (58.8)| 448 (68.1)| 0.02   |
|                                 |                         | No         | 73 (41.2)| 210 (31.9)|
effects were found to be more common in women than in men (p<0.05). In the study population, however, males used analgesia more frequently than females (p<0.05).

Medical seeking

All participants were asked; What type of analgesic they used to manage their symptoms and whether or not they had requested medical advice about their side effects following vaccination. Table 3 illustrated the frequency of use of all analgesics recorded, with paracetamol being the most commonly taken by both genders. Only a small percentage of respondents said they requested medical help to relieve their symptoms, and no significant association was found in terms of gender.

| Variables                  | Sex          | P value |
|----------------------------|--------------|---------|
| Type of analgesics used (n=533) |              |         |
| paracetamol                | 91 (92.9)    | 0.688   |
| diclofenac                 | 2 (2.0)      |         |
| ibuprofen                  | 3 (3.1)      |         |
| mefenamic acid             | 1 (1.0)      |         |
| aspirin                    | 1 (1.0)      |         |
| meloxicam                  | 0 (0.0)      |         |
| Physician consultation     |              | 0.295   |
| Yes                        | 12 (6.7)     |         |
| No                         | 167 (93.3)   |         |

DISCUSSION

This study aimed to compare males and females in aspects regarding adverse effects after receiving one or two doses of COVID-19 vaccines. This study is one of the limited studies that compared genders after receiving COVID-19 vaccines.

The largest proportion of the participants was females, as females constituted the majority of HCWs. From 2003, females represented the majority of students in medical colleges because of their higher marks on school bachelor tests, by findings published in the previous studies.13

In general side effects were minimal and tolerated and they were self-limiting in both sexes, however, females reported more adverse effects compared to males.

Similar to the findings of this study, a cross-sectional study conducted in Malaysia among general population, also females experienced more adverse events compared to males.14 In another research accomplished in Germany by Hoffman et al, to evaluate the incidence of local and systemic adverse effects following vaccination with COVID-19 vaccines, women were also more likely to experience both local and systemic side effects. However, allergic reactions and vaccination complications were not detected. These findings were similar to the reports of the Centers for Disease Control and Prevention (CDC).15

In contrast to our result, a study performed in Saudi Arabia to report post-vaccination side effects among the general population. They found that males experience more adverse effects compared to females.2

Pain at the injection site was the most prevalent adverse effect and treatments were not required for most of these respondents; as the pain was minor in most of them. Severe pain was reported more frequently among females than males. Whereas the precise reason for these gender differences is uncertain. Numerous psychosocial and biological factors appear to be important contributors. In an observational study that was done in the United Kingdom to report side effects following vaccination with Pfizer and AstraZeneca vaccines among general population, Pain at the injection site was identified in less than half of the participants and it is more common among women.16 In a study conducted by Hoffman et al, reported that 72% of females have no pain while 78% of males indicated they have no pain.15 Some theories revealed that both endogenous opioids and genetics have a fundamental role in these variations, while lots of studies imply that sex hormones influence pain sensitivity. Nevertheless, more researches into the particular modulatory influence of sex hormones on pain in male and female are needed. Along with stereotypical sex roles that may lead to disparities in pain expression, psychosocial processes including stress exposure and the ability to cope with pain could also explain the gender difference in pain threshold.17 In the aspect of systemic symptoms such as headache, tiredness, myalgia, chills and fever; women had a significantly greater incidence of moderate and severe side effects. Headache was also more common among females according to a study done by Menni et al in United Kingdom.16 In a study done in Germany, to report the incidence of adverse effects following vaccination with one of COVID-19 vaccines among HCWs, headache, chills and fever were also more common in women.18

Regarding the dermatological reactions, like swelling, skin rash and redness were also more common among female participants. In the German study, also swelling and redness were more among females, although the difference between them and males was not significant.15 Although rare, 90% of allergic responses were reported in females according to CDC report.19

In 2019, a study conducted to report vaccination side effects from 1990 to 2016 to the CDC, women reported 80% of severe allergic responses (anaphylaxis) in adults.20

Other vaccines such as the influenza H1N1 vaccine have shown that females experienced greater vaccine-related adverse effects and have higher immunological reactions than males.21 According to theories tried to explain the gender-based disparity in self-reported vaccine adverse effects of COVID-19 vaccination. Women’s sex hormones estradiol (in addition to their other roles) increases the formation of antibodies. Females also have a stronger immunological response, On the other hand, testosterone act in the opposite manner by decreasing immune response but at the same time increasing male susceptibility to viral infection.15,21,22 Furthermore, the social structure of masculinity and femininity played an important role in this issue, since women are more likely to request medical aid than men who may face several obstacles to getting assistance.
Limitation of the study

Although the sample size was high and recruitment of the studied sample population was from different cities in Iraq. The study was associated with some limitations; there was a lack of information regarding the participant’s medical history such as chronic health conditions and drugs. Since the study is a descriptive one using a cross-sectional design and an electronic questionnaire, only persons who are using the internet in regular bases are eligible to participate. The elderly and people in the rural area represented the minority of the respondents. The study was based on trust and employed subjective assessments, to obtain accurate findings direct personal interview is preferable. Researchers mainly evaluated the vaccinations’ short term side effects; a long term follow up research in the general public is needed. A more comprehensive study including all approved vaccines is also recommended.

CONCLUSION

The objective of this study was to see which gender experienced more severe adverse effects after receiving COVID-19 vaccines. The study concluded that the majority of side effects reported with COVID-19 vaccines were tolerated and not severe. However, the occurrence of these side effects was more common in women than in men which may be attributed to the hormonal and psychological variation between them. A longitudinal follow up study may give us more powerful results.

References

1. Saeed BQ, Al-Shahrabi R, Alhaj SS, et al. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219-26. https://doi.org/10.1016/j.ijid.2021.08.013
2. Adam M, Gameraddin M, Aleyani M, et al. Evaluation of Post-Vaccination Symptoms of Two Common COVID-19 Vaccines Used in Abha, Aseer Region, Kingdom of Saudi Arabia. Patient Prefer Adherence. 2021;15:1963-1970. https://doi.org/10.2147/PPA.S330689
3. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288(2):198114. https://doi.org/10.1016/j.virusres.2020.198114
4. Szymb B, Karuga FF, Bartoszek A, et al. Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland. Vaccines (Basel). 2021;9(3):218. https://doi.org/10.3390/vaccines9030218
5. Riad A, Pokorná A, Attia S, et al. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1-18. https://doi.org/10.3390/jcm10071428
6. Ciarambino T, Barbagelata E, Corbi G, et al. Gender differences in vaccine therapy: where are we in COVID-19 pandemic? Monaldi Arch Chest Dis. 2021;91(4). https://doi.org/10.4081/monaldi.2021.1669
7. Vassallo A, Shajahan S, Harris K, et al. Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain. Front Glob Womens Health. 2021;2:761511. https://doi.org/10.3389/fgwsh.2021.761511
8. Brady E, Nielsen MW, Andersen JP, et al. Lack of consideration of sex and gender in COVID-19 clinical studies. Nat Commun. 2021;12(1):8-13. https://doi.org/10.1038/s41467-021-24265-8
9. General Accounting Office (2001) Drug safety: Most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R. Available: http://www.gao.gov/new.items/d01286r.pdf. Accessed 20 April 2022.
10. Attash HM, Al-Obaidy LM, Al-Qazaz HK. Which Type of the Promising COVID-19 Vaccines Produces Minimal Adverse Effects? A Retrospective Cross-Sectional Study. Vaccines. 2022;10(1). https://doi.org/10.3390/vaccines10010018
11. Hatmal MM, Al-Hatamleh MAI, Olaimat AN, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines (Basel). 2021;9(6):556. https://doi.org/10.3390/vaccines9060556
12. El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. Int J Gen Med. 2021;14:1389-1401. https://doi.org/10.2147/IJGM.S310497
13. Al-Jumaili AA, Hussain SA, Sorofman B. Pharmacy in Iraq: history, current status, and future directions. Am J Health Syst Pharm. 2013;70(4):368-72. https://doi.org/10.2146/ajhp120415
14. Elnaem MH, Mohd Taufek NH, Ab Rahman NS, et al. COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter? Vaccines (Basel). 2021;9(10):1156. https://doi.org/10.3390/vaccines9101156
15. Hoffmann MA, Wieler HJ, Enders P, et al. Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany. Vaccines (Basel). 2021;9(8):911. https://doi.org/10.3390/vaccines9080911
16. Minni C, Klarer K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Jul;21(7):939-949. https://doi.org/10.1016/ S1473-3099(21)00224-3
17. Bartley EJ, Fillingim RB. Sex differences in pain: A brief review of clinical and experimental findings. Br J Anaesth. 2013;111(1):52-58. https://doi.org/10.1093/bja/aet127
Al-Qazaz HK, Al-Obaidy LM, Attash HM. COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study. Pharmacy Practice 2022 Apr-Jun;20(2):2678.

https://doi.org/10.18549/PharmPract.2022.2.2678

18. Nachtigall I, Bonsignore M, Hohenstein S, et al. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infect Dis. 2022;22(1):291. https://doi.org/10.1186/s12879-022-07284-8

19. Shimabukuro T, Nair N. Allergic Reactions including Anaphylaxis after Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA - J Am Med Assoc. 2021;325(8):780-781. https://doi.org/10.1001/jama.2021.0600

20. Su JR, Moro PL, Ng CS, et al. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. J Allergy Clin Immunol. 2019;143(4):1465-1473. https://doi.org/10.1016/j.jaci.2018.12.1003

21. Potluri T, Fink AL, Sylvia KE, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines. 2019;4:29. https://doi.org/10.1038/s41541-019-0124-6

22. Riad A, Pokorná A, Klugarová J, et al. Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18-30 Years Old): An Independent Post-Marketing Study. Pharmaceuticals (Basel). 2021;14(10):1049. https://doi.org/10.3390/ph14101049